Holen Sie sich die Stockscreener-App
301.28
0.25%
-0.74
Handel nachbörslich:
301.28
Schlusskurs vom Vortag:
$302.02
Offen:
$301.04
24-Stunden-Volumen:
179.53K
Relative Volume:
0.87
Marktkapitalisierung:
$8.13B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-11.02
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
-4.36%
1M Leistung:
-0.91%
6M Leistung:
+30.73%
1J Leistung:
-10.82%
1-Tages-Spanne:
$298.74
$304.91
1-Wochen-Bereich:
$298.02
$319.50
52-Wochen-Spanne:
$211.43
$373.69
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
301.28 | 8.15B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
126.71 | 220.59B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
94.48 | 137.79B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
352.58 | 134.49B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.30 | 125.28B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.84 | 49.51B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Multi Omics Platform Market Outlook 2025-2032: Key Trends, Size - openPR.com
DNA/RNA Extraction Kit Market to Reach US$ 5.12 Billion by 2033 - openPR.com
Fragment Analysis Market 2025-2032: Growth Overview, Facts & - openPR.com
Biodesix and Bio-Rad Laboratories Team Up on Droplet Digital PCR Assays - Medical Product Outsourcing
Is Bio-Rad (BIO) Quietly Repositioning Its Moat Around Automation‑Led Blood Diagnostics? - Sahm
IVD Diagnostic Molecule Raw Enzymes Market Forecast to Grow at 7.13% CAGR by 2034 - GlobeNewswire Inc.
MASTERINVEST Kapitalanlage GmbH Acquires New Shares in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
United States DNA Sequencing Market 2031 | Growth Drivers, Key - openPR.com
Bio-Rad launches TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits for antibody conjugation to StarBright Dyes - MSN
Bio-Rad Laboratories, Inc. $BIO Shares Acquired by HRT Financial LP - MarketBeat
Hound Partners LLC Has $43.91 Million Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Improving research efficiency with high-performance flow cytometry - News-Medical
Becton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety - GlobeNewswire
Becton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety and Automation in Blood Collection Tubes—New Market Report Highlights $7Billion Opportunity - Yahoo Finance
Bio-Rad, Poly Medicure, and Sekisui Medical Power Rapid - GlobeNewswire
Bio-Rad, Poly Medicure, and Sekisui Medical Power Rapid Expansion in the Venous Blood Collection Market Through 2032 - Yahoo Finance
What Makes Bio-Rad Laboratories (BIO) an Investment Bet? - MSN
Ilex Capital Partners UK LLP Acquires 114,490 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
United States Microfluidics Devices Market Expands Rapidly - openPR.com
Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR high complexity assays - MSN
Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued? - 富途牛牛
Federated Hermes Inc. Has $30.66 Million Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Ariel Investments LLC Has $197.55 Million Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Polymerase Chain Reaction (PCR) Market Rapid Growt 2025-2033: - openPR.com
Basic Statistics in Laboratory Quality Control - Labroots
Norges Bank Makes New Investment in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
JPMorgan Chase & Co. Has $12.97 Million Stock Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Why (BIO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What is the fair value estimate for Bio Rad Laboratories Inc. (BUW) stock in 2025Market Sentiment Summary & High Conviction Buy Zone Picks - Newser
What insider purchases suggest about Bio Rad Laboratories Inc. Class stockEarnings Miss & Low Risk High Reward Ideas - Newser
How Bio Rad Laboratories Inc. (BUWA) stock performs in volatility spikesJuly 2025 Analyst Calls & Precise Buy Zone Tips - Newser
Why Bio Rad Laboratories Inc. (BUW) stock is upgraded to buyJuly 2025 EndofMonth & High Accuracy Swing Entry Alerts - Newser
Is Bio Rad Laboratories Inc. Class B stock a good hedge against inflationWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Why Bio Rad Laboratories Inc. (BUW) stock could break out in 2025Analyst Upgrade & Stock Market Timing Techniques - Newser
Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSys - pharmiweb.com
Will Bio Rad Laboratories Inc. (BUWA) stock recover faster than industryTrade Entry Summary & Long-Term Safe Return Strategies - Newser
Will Bio Rad Laboratories Inc. (BUW) stock deliver compounding returnsGap Down & Weekly Watchlist for Hot Stocks - Newser
Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and MoreResearchAndMarkets.com - The AI Journal
Can Bio Rad Laboratories Inc. Class stock expand revenue streams2025 Year in Review & Weekly Top Gainers Alerts - Newser
How geopolitical risks impact Bio Rad Laboratories Inc. (BUWA) stockTrade Exit Report & Consistent Profit Trading Strategies - Newser
Why Bio Rad Laboratories Inc. stock is in analyst buy zoneEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Will Bio Rad Laboratories Inc. (BUW) stock outperform energy sector in 2025Share Buyback & Free Weekly Watchlist of Top Performers - Newser
Why Bio Rad Laboratories Inc. (BUWA) stock is a must watch tickerEntry Point & Long-Term Capital Growth Strategies - Newser
Will Bio Rad Laboratories Inc. (BUW) stock recover faster than industry - Newser
Can Bio Rad Laboratories Inc. (BUWA) stock resist broad market declinesJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Circulating Biomarkers Market Projections 2025-2032: Key - openPR.com
Next Generation Sequencing Library Preparation Market - openPR.com
Hydroxyapatite Market Size, Scope 2031 by Key Companies- Zimmer - openPR.com
Fisher Asset Management LLC Sells 5,884 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Share Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):